AMD

Ophthalmology·MeSH: Wet Macular Degeneration

Prevalence

81.8 / 100K

29 drugs in development·18 companies·4 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
prednisolone	Amneal Pharmaceuticals, Inc. (AMRX)
prednisone	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(16)

Drug	Company
150 ivt	4D Molecular Therapeutics, Inc. (FDMT)
4D-150 IVT	Merus N.V. (MRUS)
ABBV-RGX-314	REGENXBIO Inc. (RGNX)
AXPAXLI	OCULAR THERAPEUTIX, INC (OCUL)
cemdisiran	REGENERON PHARMACEUTICALS, INC. (REGN)
cemdisiran	West Pharmaceutical Services Inc. (WST)
eylea	4D Molecular Therapeutics, Inc. (FDMT)
eylea	4D Molecular Therapeutics, Inc. (FDMT)
ixo-vec	Adverum Biotechnologies, Inc. (ADVM)
Ixo-vec (formerly ADVM-022)	Adverum Biotechnologies, Inc. (ADVM)
ixoberogene soroparvovec (Ixo-vec; formerly ADVM-022)	Adverum Biotechnologies, Inc. (ADVM)
lx102	SAB BIOTHERAPEUTICS, INC. (SABS)
m710	MOMENTA PHARMACEUTICALS INC (MNTA)
OTX-TKI	OCULAR THERAPEUTIX, INC (OCUL)
pozelimab	West Pharmaceutical Services Inc. (WST)
surabgene lomparvovec (sura-vec	REGENXBIO Inc. (RGNX)

Phase 2(2)

Drug	Company
opregen	Lineage Cell Therapeutics, Inc. (LCTX)
th103	Kalaris Therapeutics, Inc. (KLRS)

Phase 1(2)

Drug	Company
HiPSC-RPE cells	Amneal Pharmaceuticals, Inc. (AMRX)
NK Cells	Amneal Pharmaceuticals, Inc. (AMRX)

Preclinical(5)

Drug	Company
ar-14034 sr	AERIE PHARMACEUTICALS INC (AERI)
dry amd gene therapy	APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
inm-089	InMed Pharmaceuticals Inc. (INM)
szn-8141	Surrozen Inc. (SRZN)
szn-8143	Surrozen Inc. (SRZN)

BLA Filed(1)

Drug	Company
ons-5010/lytenava	Outlook Therapeutics, Inc. (OTLK)

Phase 2/Phase 3(1)

Drug	Company
abbv-rgx-314	AbbVie Inc. (ABBV)

BioSniper tracks 29 drugs in development for AMD across 18 companies.

There are 4 clinical trials targeting AMD tracked by BioSniper.

The estimated prevalence of AMD is approximately 81.8 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.